Chris Freeman - 15 Mar 2026 Form 4 Insider Report for Guardant Health, Inc. (GH)

Role: Chief Commercial Officer
Signature: /s/ John G. Saia, as attorney-in-fact for Chris Freeman
Issuer symbol: GH
Transactions as of: 15 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 17 Mar 2026, 18:48:14 UTC
Previous filing: 13 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Freeman Chris	Chief Commercial Officer	3100 HANOVER STREET, PALO ALTO	/s/ John G. Saia, as attorney-in-fact for Chris Freeman	17 Mar 2026	0001871615

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GH	Common Stock	Options Exercise		+15,426	+35%	$0.000000^*	59,296	15 Mar 2026	Direct
transaction	GH	Common Stock	Options Exercise		+1,402	+2.4%	$0.000000^*	60,698	15 Mar 2026	Direct
transaction	GH	Common Stock	Tax liability		-7,127	-12%	$85.49^*	53,571	15 Mar 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GH	Performance-Based Restricted Stock Units	Options Exercise		-15,426	-100%	$0.000000^*	0	15 Mar 2026	Common Stock	15,426	$0.000000	Direct	F2, F3
transaction	GH	Restricted Stock Units	Options Exercise		-1,402	-50%	$0.000000^*	1,402	15 Mar 2026	Common Stock	1,402	$0.000000	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2	This represents a performance-based restricted stock unit award granted on June 7, 2023 with a 3-year performance metric. The second tranche metric was achieved and the shares vested on March 15, 2026.
F3	Not applicable for Restricted Stock Units.
F4	This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.